Skip to main content

Lower Limb Ischemia

1
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Boston Scientific
Boston ScientificCA - Valencia
1 program
1
Ranger SL DEBPhase 2/31 trial
Active Trials
NCT02856230Unknown30Est. Nov 2018
Genesis Therapeutics
Genesis TherapeuticsCA - Burlingame
1 program
ASC coated ePTFE vascular graftN/A
Tissue Genesis
Tissue GenesisTX - Leander
1 program
ASC coated ePTFE vascular graftN/A1 trial
Active Trials
NCT01305863Unknown60Est. May 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Boston ScientificRanger SL DEB
Tissue GenesisASC coated ePTFE vascular graft

Clinical Trials (2)

Total enrollment: 90 patients across 2 trials

An Efficacy and Safety Study to Evaluate Ranger DEB for BTK Angioplasty in Patients With CLI (RANGER-BTK)

Start: Nov 2016Est. completion: Nov 201830 patients
Phase 2/3Unknown
NCT01305863Tissue GenesisASC coated ePTFE vascular graft

Feasibility Study of the TGI Adipose-derived Stromal Cell (ASC)-Coated ePTFE Vascular Graft

Start: Feb 2011Est. completion: May 202260 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.